Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001230015 | SCV001402482 | uncertain significance | Congenital muscular dystrophy due to integrin alpha-7 deficiency | 2023-08-10 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 957098). This variant has not been reported in the literature in individuals affected with ITGA7-related conditions. This variant is present in population databases (rs758978382, gnomAD 0.0009%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 149 of the ITGA7 protein (p.Arg149Gln). |
Ambry Genetics | RCV004032687 | SCV003758636 | uncertain significance | not specified | 2022-07-26 | criteria provided, single submitter | clinical testing | The c.446G>A (p.R149Q) alteration is located in exon 4 (coding exon 4) of the ITGA7 gene. This alteration results from a G to A substitution at nucleotide position 446, causing the arginine (R) at amino acid position 149 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001230015 | SCV003811444 | uncertain significance | Congenital muscular dystrophy due to integrin alpha-7 deficiency | 2019-11-14 | criteria provided, single submitter | clinical testing |